Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

NCT05432193 is registered in ClinicalTrials.gov with POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company as lead sponsor.

NCT NCT05432193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05432193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
July 13, 2022
Completion date
October 2, 2024
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal cancer, esophageal cancer, head and neck squamous cell carcinoma, melanoma (skin), pancreatic ductal adenocarcinoma, soft tissue sarcoma